Market closed
Pliant Therapeutics/$PLRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Ticker
$PLRX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
166
Website
PLRX Metrics
BasicAdvanced
$864M
Market cap
-
P/E ratio
-$3.34
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$864M
Beta
1.09
52-week high
$19.62
52-week low
$10.22
Average daily volume
484K
Financial strength
Current ratio
10.263
Quick ratio
10.18
Long term debt to equity
17.318
Total debt to equity
17.412
Interest coverage (TTM)
-88.44%
Management effectiveness
Return on assets (TTM)
-28.15%
Return on equity (TTM)
-47.52%
Valuation
Price to book
2.5
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
-6.267
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
20.51%
3-year earnings per share growth (CAGR)
9.21%
What the Analysts think about PLRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pliant Therapeutics stock.
PLRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PLRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PLRX News
AllArticlesVideos
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
GlobeNewsWire·3 weeks ago
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
GlobeNewsWire·2 months ago
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pliant Therapeutics stock?
Pliant Therapeutics (PLRX) has a market cap of $864M as of December 13, 2024.
What is the P/E ratio for Pliant Therapeutics stock?
The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of December 13, 2024.
Does Pliant Therapeutics stock pay dividends?
No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Pliant Therapeutics dividend payment date?
Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Pliant Therapeutics?
Pliant Therapeutics (PLRX) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.